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PhenotypeHereditary spastic paraplegia (HSP) is a group of clinically and genetically heterogeneous neurological disorders
characterized by pathophysiologic hallmark of length-dependent distal axonal degeneration of the corticospinal
tracts. The prominent features of this pathological condition are progressive spasticity andweakness of the lower
limbs. To date, 72 spastic gait disease-loci and 55 spastic paraplegia genes (SPGs) have been identiﬁed. All modes
of inheritance (autosomal dominant, autosomal recessive, and X-linked) have been described. Recently, a late
onset spastic gait disorder with maternal trait of inheritance has been reported, as well as mutations in genes
not yet classiﬁed as spastic gait disease. Several cellular processes are involved in its pathogenesis, such as mem-
brane and axonal transport, endoplasmic reticulum membrane modeling and shaping, mitochondrial function,
DNA repair, autophagy, and abnormalities in lipid metabolism and myelination processes. Moreover, recent ev-
idences have been found about the impairment of endosome membrane trafﬁcking in vesicle formation and
about the involvement of oxidative stress and mtDNA polymorphisms in the onset of the disease. Interactome
networks have been postulated by bioinformatics and biological analyses of spastic paraplegia genes, which
would contribute to the development of new therapeutic approaches.
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Hereditary spastic paraplegias (HSPs) constitute a heterogeneous group
of neurodegenerative diseases characterized by genetic mutations that
cause distal neuropathy of the longest corticospinal tract axons (Harding,
1993) ; ascending ﬁbers (column of Goll and spinocerebellar tracts) are
also often involved (reviewed in Blackstone, 2012; Deluca et al., 2004;
reviewed in Orlacchio et al., 2006). As a result of corticospinal dysfunction,
progressive weakness and spasticity, extensor plantar responses, andhyperreﬂexia of deep tendon reﬂexes in lower limbs are common clinical
features in pure forms. Iliopsoas, quadriceps femoris, and tibialis anterior
are themusclesmost affected by spasticity andweakness. Hypertonic blad-
der and lower limb sensory disturbances (generally mild, regarding vibra-
tion and joint position sense) may be present in pure forms too.
Other manifestations may occur in complicated forms, including
above all cognitive impairment, cerebellar atrophy, polyneuropathy,
thin corpus callosum (TCC), epilepsy, skeletal abnormalities,
amyotrophy, and optic atrophy.
520 T. Lo Giudice et al. / Experimental Neurology 261 (2014) 518–539Age of onset is early childhood through 70 years. A recent sys-
tematic review from 12 studies performed since 1985 in European,
Asian, and North African countries, estimated a global average prev-
alence of 1.8/105 for both ADHSP and ARHSP (reviewed in Ruano
et al., 2014). Pure forms are more prevalent in Northern Europe,
Japan, and North America (Braschinsky et al., 2009; Ishiura et al.,
2014). Complicated forms are generally inherited as autosomal re-
cessive traits (Coutinho et al., 1999). In Mediterranean countries,
these forms are more common due to the increased frequency of
consanguinity.
To date, 72 different spastic gait disease-loci have been identiﬁed,
and 55 spastic paraplegia genes (SPGs) have already been cloned.
Other HSP causative genes are not in the SPG classiﬁcation yet.
This review focuses on the clinical features and diagnostic clues
for each genetic subtype of HSP, and on molecular pathogenesis in-
cluding mitochondrial dysfunctions, the involvement of mitochon-
drial DNA polymorphisms/haplogroups and of oxidative stress in
the disease. The recent discoveries of new causative genes also high-
light the importance of ER function, morphogenesis, membrane
shaping and endosome membrane trafﬁcking, and vesicle formation
in HSP pathophysiology.
Genetic classiﬁcation of HSP
HSP can be transmitted in an autosomal dominant (AD), autosomal
recessive (AR), X-linked (XL), or mitochondrial manner (reviewed in
Finsterer et al., 2012; reviewed in Schüle and Schöls, 2011). Nonethe-
less, sporadic HSP due to true de novomutations, genealogical censure,
non-penetrant AD mutations, or singleton in unrecognized AR kindred,
is common. Fig. 1 shows the most frequent HSP causative genes. HSPFig. 1.Timeline of genediscoveries and frequencies of themost frequent causative genes in fami
affected subjects from all over the world).forms and putative protein function of each HSP gene product are sum-
marized in Table 1. Inheritance and clinical features of each HSP form
are described in Table 2.
ADHSP
To date, 20 genetic SPG loci for ADHSP have been identiﬁed, but only
12 genes are known. There are at least eight identiﬁedADHSP lociwith an
uncloned gene associated with the disease in both pure and complicated
forms (Tables 1 and 2): SPG9 (Panza et al., 2008; Seri et al., 1999), SPG19
(Valente et al., 2002), SPG29 (Orlacchio et al., 2005a), SPG36 (Schüle et al.,
2009a), SPG37 (Hanein et al., 2007), SPG38 (Orlacchio et al., 2008b),
SPG40 (Subramony et al., 2009), and SPG41 (Zhao et al., 2008).
SPG3A
SPG3A/ATL1mutations represent approximately 10% of ADHSP pa-
tients and are the most frequent cause of HSP with onset before age
10 years (Namekawa et al., 2006).
ATL1 encodes atlastin-1, a member of the dynamin family of large
guanosine triphosphatases, implicated in neurite outgrowth, intracellu-
lar membrane trafﬁcking, but mainly in ER and Golgi morphogenesis,
and in axon elongation during neuronal development (Byrnes and
Sondermann, 2011; Rismanchi et al., 2008).
Mutations are predominantly of missense type and whole genome
and in-frame deletions have also been reported. Whole genome dele-
tion of ATL1 was found in an SPG4 family, which did not co-segregate
with the disease (Beetz et al., 2007). A patient carrying the in-frame de-
letion of residue 436 (436delN) showed decreased atlastin-1 levels in
lymphoblasts, but normal levels of mRNA, normal GTPase activity, and
normal protein interactions. These features indicate that the pathogeniclial (A) and sporadic (B)HSP. Epidemiological data of theHSP Italian network (total of 1707
521T. Lo Giudice et al. / Experimental Neurology 261 (2014) 518–539mechanism for SPG3A is not simply due to haploinsufﬁciency. A
dominant-negative loss-of-function mechanism has been postulated
(Meijer et al., 2007).
The age of onset is around 4 years or,more rarely, later than that age.
Very early onset cases develop severe spastic gait, contrary to late onset.
Pure forms are the most common; additional symptoms include axonal
polyneuropathy of small hand muscles (Silver syndrome) and TCC
(Al-Maawali et al., 2011; Fusco et al., 2010; reviewed in Hedera, 2010;
Orlacchio et al., 2011).
SPG4
About 40% of ADHSP and about 20% of sporadic HSP are caused by
mutations in SPG4/SPAST (Fig. 1), encoding spastin (Hazan et al.,
1999). Spastin is amember of the ATPases associatedwith diverse cellu-
lar activities (AAA) family, with roles in microtubule dynamics and
membrane trafﬁcking. Four kinds of SPASTmRNA have been discovered,
depending on the translation initiation codon used and alternative
splicing of the exon 4 (reviewed in Salinas et al., 2007). Spastin has
twomain structural domains: themicrotubule interacting and transport
(MIT) domain at the N-terminus, and the AAA catalytic domain in C-
terminus. Over 300 mutations, including partial deletions, have been
described; all pathogenic gene variants appear to affect the AAA do-
main, and act by a loss-of-function mechanism (haploinsufﬁciency)
(Beetz et al., 2006). Recently, intragenic copy-number variations have
been found to cause the disease (Depienne et al., 2007). The high
concentration of Alu (highly homologous non low-copy repeats in-
terspersed repetitive sequences) family members in the introns
and ﬂanking sequence of SPAST may predispose to intragenic
rearrangements.
Most SPG4-patients show a pure phenotype, with average onset in
the fourth decade of life, variably accompanied by column sensory def-
icits and, in about one third of cases, bladder disturbance (McDermott
et al., 2006; Orlacchio et al., 2008a; Schulte et al., 2003). SPG4 embraces
a wide phenotypic variation, including the Silver syndrome (Orlacchio
et al., 2008b). The excess of males in published reports suggests that
penetrance or severity may be sex-dependent (Orlacchio et al., 2005b;
Proukakis et al., 2011). Phenotypes complicated by cognitive impair-
ment in executive functions (Ribaï et al., 2008) and by posterior fossa
abnormalities (congenital arachnoid cysts) (Orlacchio et al., 2004a)
have been reported.
SPG6
SPG6 is caused by mutations in NIPA1 (Kaneko et al., 2006; Munhoz
et al., 2006; Rainier et al., 2003). It comprises ﬁve exons encoding the
non-imprinted in Prader-Willi/Angelman syndrome region protein 1.
Pure forms, with severe and rapidly progressive spasticity, are the
majority. Polyneuropathy, cognitive impairment, and epilepsy are also
reported (Du et al., 2011; Klebe et al., 2007; Svenstrup et al., 2011).
SPG8
SPG8/KIAA0196 encodes strumpellin, a protein ubiquitously
expressed and localized in cytoplasm and endoplasmic reticulum (ER).
KIAA0196 mutations, reported in a few families with pure HSP (de Bot
et al., 2013; Rocco et al., 2000), lead to reduction of axonal outgrowth
with a loss-of-function mechanism (Clemen et al., 2010) disrupting
the endosome membrane trafﬁcking (Freeman et al., 2013).
SPG10
SPG10 is caused by mutations in KIF5A (Reid et al., 2002). This gene
codes for kinesin HC5A, a kinesin heavy chain. Most of KIF5Amutations
are located in the highly conserved kinesin motor domain. Functional
analyses showed an altered axonal transport, reducing the cargo ﬂux
and leading to deﬁcient supply of the synapse (Ebbing et al., 2008).
A recent study of ADHSP Western European families reported that
SPG10 accounts for about 10% of complicated forms (Goizet et al.,2009c). Moreover, a new phenotype present in SPG10 includes
dysautonomia (Collongues et al., 2013).
SPG12
SPG12/RTN2 encodes reticulon 2, a protein belonging to a large and
diverse group of membrane-associated proteins found throughout the
eukaryotic kingdom and named reticulons. These proteins regulate ER
structure and functions and contain a uniquely conserved C-terminal
domain (reticulon homology domain, RHD). RHD contains two putative
transmembrane domains (TM1 and TM2), a loop region and a short N-
terminus (reviewed in Chiurchiù et al., 2014). Reticulon 2 interacts with
spastin. Mutations can be frameshift, missense, and whole gene dele-
tion, presumably leading to haploinsufﬁciency. SPG12 is a pure and
rapid progressive HSP (Montenegro et al., 2012; Orlacchio et al., 2002).
SPG13
SPG13/HSPD1 encodes a mitochondrial protein, the heat shock pro-
tein 60 chaperone (Hsp60), which assists the folding of several proteins
localized in mitochondria.
SPG13 occurs between 1 and 60 years of age; in addition to pure
form with loss of vibratory sensation, it was associated with dystonia,
which improves upon deep brain stimulation (Gilbert et al., 2009;
Hansen et al., 2002).
SPG17
SPG17/BSCL2 encodes seipin, an ER integral membrane protein
whose function is unknown. The two identiﬁed missense mutations af-
fect its glycosylation and result in an accumulation of unfolded protein
in the ER. This probably triggers the unfolded protein response (UPR)
and cell death, suggesting that these diseases are tightly associated
with ER stress.
SPG17 causes Silver syndrome that includes amyotrophy of small
handmuscles. Nerve conduction studies often disclose severe reduction
of compound muscle action potentials (CMAPs) (Windpassinger et al.,
2004).
SPG17 is allelic to congenital generalized lipodystrophy type 2 (also
termed Berardinelli–Seip congenital lipodystrophy), distal hereditary
motor neuropathy type V (dHMNV), and Charcot–Marie–Tooth disease
2 (CMT2) (reviewed in Ito and Suzuki, 2009).
SPG31
SPG31/REEP1 encodes the receptor expression-enhancing protein 1,
a mitochondrial protein that might be involved in chaperon-like activi-
ties. Missense, splice site, nonsense, insertion and deletion mutations
are known. Loss of function and haploinsufﬁciency are themajor mech-
anisms of action in SPG31 (Battini et al., 2011). Functional studies
showed abnormal mitochondrial network organization in ﬁbroblasts
of one patient, in addition to defectivemitochondrial energy production
(Goizet et al., 2011).
Only a fewpatients show a complicatedHSP form (Beetz et al., 2008;
Goizet et al., 2011).
SPG33
SPG33 was reported in a single German family with complicated HSP
and mutation (p.G191V) in ZFYVE27 (Mannan et al., 2006). It encodes a
speciﬁc spastin-binding protein, protrudin, a member of the FYVE-ﬁnger
family of proteins. The mutated protein shows an aberrant intracellular
pattern in its tubular structure impairing its interaction with spastin and
affecting neuronal intracellular trafﬁcking in the corticospinal tract.
The disease-related role remains unsettled (Martignoni et al., 2008).
SPG42
SPG42/SLC33A1 encodes the acetyl-CoA transporter, a multiple trans-
membrane protein in the ER. It carries acetyl-CoA into the lumen of Golgi
apparatus, where it is transferred to the sialyl residues of gangliosides and
glycoproteins. This modiﬁcation may play a critical role in the outgrowth
Table 1
HSP loci/genes and protein putative function of each HSP form.
Type Locationa Gene/Protein Exonsb TOM OMIM Gene/locus Phenotype PPF References c
SPG1 Xq28 L1CAM/NCAM 29 PM MIM308840 MIM303350 Neuronal cell adhesion and signaling Jouet et al. (1994)
SPG2 Xq22.2 PLP1/MPLP 8 PM, del, dupl MIM300401 MIM312920 Myelination and axonal survival Saugier-Veber et al. (1994)
SPG3A 14q22.1 ATL1/ATLASTIN-1 14 PM MIM606439 MIM182600 Neurite outgrowth, membrane trafﬁcking, ER and
Golgi
morphogenesis
Zhao et al. (2001)
SPG4 2p22.3 SPAST/SPASTIN 17 PM, ss, del, dupl,
ins
MIM604277 MIM182601 Microtubule dynamics, membrane trafﬁcking, ER
morphogenesis, BMP signaling
Hazan et al. (1999)
SPG5A 8q12.3 CYP7B1/OAH1 6 PM MIM603711 MIM270800 Brain cholesterol metabolism Tsaousidou et al. (2008)
SPG6 15q11.2 NIPA1/NIPA1 5 PM MIM608145 MIM600363 Cellular magnesium ion metabolism, endosomal/ER
morphogenesis, protein folding
Rainier et al. (2003)
SPG7 16q24.3 PGN/PARAPLEGIN 17 PM, del, ins MIM602783 MIM607259 Mitochondrial protease, ribosome maturation Casari et al. (1998)
SPG8 8q24.13 KIAA0196/STRUMPELLIN 29 PM, del MIM610657 MIM603563 Endosomal morphogenesis, protein folding Valdmanis et al. (2007)
SPG9 10q23.3–24.2 – – – MIM601162 Unknown Seri et al. (1999)
SPG10 12q13.3 KIF5A/KINESIN HC5A 29 PM MIM602821 MIM604187 Microtubule-based motor protein Reid et al. (2002)
SPG11 15q21.1 KIAA1840/SPATACSIN 40 PM, dupl, ins, del,
ss
MIM610844 MIM604360 Vesicles sorting Stevanin et al. (2007b)
SPG12 19q13.32 RTN2/RETICULON 2 11 PM, ins, del MIM603183 MIM604805 ER morphogenesis Montenegro et al. (2012)
SPG13 2q33.1 HSPD1/HSP60 12 PM MIM118190 MIM605280 Protein folding and assembly in mitochondria Hansen et al. (2002)
SPG14 3q27–q28 – – – MIM605229 Unknown Vazza et al. (2000)
SPG15 14q24.1 ZFYVE26/SPASTIZIN 42 PM, del, ss MIM612012 MIM220700 Endosomal trafﬁcking, authophagy, cytokinesis Hanein et al. (2008)
SPG16 Xq11.2 – – – MIM300266 Unknown Steinmuller et al. (1997)
SPG17 11q12.3 BSCL2/SEIPIN 12 PM MIM606158 MIM270685 Lipid metabolism, ER stress response Windpassinger et al. (2004)
SPG18 8p11.23 ERLIN2/SPFH2 12 Del MIM611605 MIM611225 Regulation of ERAD pathway Alazami et al. (2011)
SPG19 9q – – – MIM607152 Unknown Valente et al. (2002)
SPG20 13q13.3 SPG20/SPARTIN 9 PM, del MIM607111 MIM2759002 Protein folding, turnover in mitochondria and
microtubule dynamics
Patel et al. (2002)
SPG21 15q22.31 ACP33/MASPARDIN 9 PM, ins MIM608181 MIM248900 Endosomal trafﬁcking and sorting Simpson et al. (2003)
SPG22 Xq13.2 SLC16A2/MCT8 6 PM, del, ins MIM30095 MIM300523 Membrane transporter (axon development) Schwartz et al. (2005)
SPG23 1q24–q32 – – – MIM270750 Unknown Blumen et al. (2003)
SPG24 13q14 – – – MIM607584 Unknown Hodgkinson et al. (2002)
SPG25 6q23–q24.1 – – – MIM608220 Unknown Zortea et al. (2002)
SPG26 12p11.1–q14 B4GALNT1/B4GALNT1 11 PM, del, dupl MIM601873 MIM609195 Ganglioside biosynthesis Boukhris et al. (2013)
SPG27 10q22.1–q24.1 – – – MIM609041 Unknown Meijer et al. (2004)
SPG28 14q22.1 DDHD1/PAPLA1 13 PM, del MIM614603 MIM609340 Fatty-acid and/or phospholipid metabolism Tesson et al. (2012)
SPG29 1p31.1–p21.1 – – – MIM609727 Unknown Orlacchio et al. (2005a)
SPG30 2q37.3 KIF1A/KINESIN3 50 PM MIM601255 MIM610357 Αnterograde transport Erlich et al. (2011)
SPG31 2p11.2 REEP1/REEP1 7 PM, del, ss, ins MIM609139 MIM610250 Chaperon-like activities, ER morphogenesis Züchner et al. (2006)
SPG32 14q12–q21 – – – MIM611252 Unknown Stevanin et al. (2007a)
SPG33 10q24.2 ZFYVE27/PROTRUDIN 12 13 PMd MIM610243 MIM610244 Speciﬁc spastin binding protein Mannan et al. (2006)
SPG34 Xq24–q25 – – MIM300750 Unknown Macedo-Souza et al. (2008)
SPG35 16q23.1 FA2H/FA2H 7 PM, del MIM611026 MIM612319 Sphingolipids synthesis Dick et al. (2010)
SPG36 12q23–q24 – – – MIM613096 Unknown Schüle et al. (2009a)
SPG37 8p21.1–q13.3 – – – MIM611945 Unknown Hanein et al. (2007)
SPG38 4p16–p15 – – – MIM612335 Unknown Orlacchio et al. (2008b)
SPG39 19p13.2 NTE/PNPLA6 34 PM, ins MIM603197 MIM612020 Maintain the integrity of motor neurons,
phospholipid homeostasis
Rainier et al. (2008)
SPG40 Reserved – – – – – Subramony et al. (2009)
SPG41 11p14.1–p11.2 – – – MIM613364 Unknown Zhao et al. (2008)












SPG43 19p13.11–q12 C19orf12/C19ORF12 3 PM, del MIM614297 MIM615043 Unknown Landouré et al. (2013)
SPG44 1q42.13 GJC2/CONNEXIN 47 2 PM MIM608803 MIM613206 Formation of gap junctions, direct cell-to cell diffusion
of ions and small molecules
Orthmann-Murphy et al. (2009)
SPG45 10q24.3–q25.1 – – – MIM613162 Unknown Dursun et al. (2009)
SPG46 9p13.3 GBA2/GBA2 18 PM, dupl MIM609471 MIM614409 Ganglioside biosynthesis Martin et al. (2013)
SPG47 1p13.2 AP4B1/AP4B1 10 Ins, del MIM607245 MIM614066 Vesicle formation, molecular cargo Abou Jamra et al. (2011)
SPG48 7p22.1 KIAA0415/AP5Z1 17 Indel MIM613653 MIM613647 Helicase that repair DNA double-strand break and
interacts with spatacsin and spastizin
Słabicki et al. (2010)
SPG49 14q32.31 TECPR2/KIAA0329 20 MIM615000 MIN615031 Intracellular autophagy Oz-Levi et al. (2012)
SPG50 7q22.1 AP4M1/AP4M1 15 Ss MIM602296 MIM612936 Vesicle formation, molecular cargo Abou Jamra et al. (2011)
SPG51 15q21.2 AP4E1/AP4E1 21 Ss MIM607244 MIM613744 Vesicle formation, molecular cargo Abou Jamra et al. (2011)
SPG52 14q12 AP4S1/AP4S1 6 PM MIM607243 MIM614067 Vesicle formation, molecular cargo Abou Jamra et al. (2011)
SPG53 8p22 VPS37A/VPS37A 12 PM MIM609927 MIM614898 Sorting of ubiquitinated transmembrane proteins into
internal vesicles
Zivony-Elboum et al. (2012)
SPG54 8p11.23 DDHD2/DDHD2 18 PM, ins, ss MIM615003 MIM615033 Intracellular phospholipase Schuurs-Hoeijmakers et al. (2012)
SPG55 12q24.31 C12orf65/C12ORF65 3 PM MIM613541 MIM615035 Peptide chain termination in the mitochondrial
translation machinery
Shimazaki et al. (2012)
SPG56 4q25 CYP2U1/CYP2U1 5 PM, del MIM610670 MIM615030 Fatty acids hydroxylation Tesson et al. (2012)
SPG57 3q12.2 TFG/TFG 8 PM MIM602498 MIM604484 Oncogenesis and vesicle biogenesis and trafﬁcking Beetz et al. (2013)
SPG58 17p13.2 KIF1C/KINESIN FAMILY MEMBER 1C 23 PM, del MIM603060
MIM611302
Retrograde Golgi to ER transport Novarino et al. (2014)
SPG59 15q21.2 USP8/UBIQUITIN-SPECIFIC PROTEASE 8 21 PM MIM603158 Deubiquitinating enyzme Novarino et al. (2014)
SPG60 3p22.2 WDR48/WD REPAET DOMAIN 48 19 Del MIM612167 Regulator of deubiquitination Novarino et al. (2014)
SPG61 16p12.3 ARL6IP1/ADP-RIBOSYLATION FACTOR-LIKE 6
INTERACTING PROTEIN 1
6 Del MIM607669 Protein transport Novarino et al. (2014)
SPG62 10q24.31 ERLIN1/ER LIPID RAFT ASSOCIATED 1 11 PM MIM611604 ER-associated degradation Novarino et al. (2014)
SPG63 1p13.3 AMPD2/ADENOSINE MONOPHOSPHATE DEAMI-
NASE 2
18 Del MIM102771 Deaminates AMP to IMP in purine nucleotide metabo-
lism
Novarino et al. (2014)
SPG64 10q24.1 ENTPD1/ECTONUCLEOSIDE TRIPHOSPHATE
DIPHOSPHOHYDROLASE 1
10 PM MIM601752 Hydrolyzes ATP and other nucleotides to regulate
purinergic transmission
Novarino et al. (2014)
SPG65 10q24.32–
q24.33
NT5C2/5′-NUCLEOTIDASE, CYTOSOLIC II 18 PM, ss MIM600417 Preferentially hydrolyzes IMP, in both purine/pyrimi-
dine
nucleotide metabolism
Novarino et al. (2014)
SPG66 5q32 ARSI/ARYLSULFATASE FAMILY, MEMBER I 2 Ins MIM610009 Hydrolyze sulfate esters, hormone biosynthesis Novarino et al. (2014)
SPG67 2q33.1 PGAP1/POST-GPI ATTACHMENT TO PROTEINS 1 27 Ss MIM611655 GPI biosynthesis Novarino et al. (2014)
SPG68 11q13.1 FLRT1/FIBRONECTIN LEUCINE RICH
TRANSMEMBRANE PROTEIN 1
2 PM MIM604806 Cell adhesion and receptor signaling Novarino et al. (2014)
SPG69 1q41 RAB3GAP2/RAB3 GTPASE ACTIVATING PROTEIN
SUBUNIT 2 (NON-CATALYTIC)
35 PM MIM609275 Exocytosis of neurotransmitters and hormones Novarino et al. (2014)
SPG70 12q13 MARS/METHIONYL-TRNA SYNTHETASE 21 PM MIM156560 Cytosolic methionyl-tRNA synthetase Novarino et al. (2014)
SPG71 5p13.3 ZFR/ZINC FINGER RNA-BINDING PROTEIN 20 PM - RNA localization? Novarino et al. (2014)
SPG72 5q31 REEP2/RECEPTOR EXPRESSION-ENHANCING
PROTEIN 2
8 PM MIM609347 ER-shaping protein Esteves et al. (2014), Novarino et al.
(2014)
Ua 2q31.1 GAD1/GLUTAMATE DECARBOXYLASE 1 17 PM MIM605363 MIM603513 GABA synthesis Lynex et al. (2004)
Ua 5p15.2 CCT5/ε SUBUNIT OF THE CYTOSOLIC CHAPERONIN
CONTAINING T-COMPLEX PEPTIDE-1
11 PM MIM610150 MIM256840 Proteins folding and cytosolic proteins assembly Bouhouche et al. (2006)
Ua 19q13.32 OPA3/OPTIC ATROPHY 3 PROTEIN 3 PM MIM606580 MIM258501 Regulator of mitocondrial activity Arif et al. (2013)
Ua 9q22.31 BICD2/BICAUDAL D HOMOLOG 2 7 PM MIM609797 Protein transport Novarino et al. (2014)
Ua 19q13.1 MAG/MYELIN ASSOCIATED GLYCOPROTEIN 12 PM MIM159460 Component of myelin Novarino et al. (2014)
Ua 1q42.3 LYST/LYSOSOMAL TRAFFICKING REGULATOR 53 PM MIM214500 Lysosomal trafﬁcking regulator Shimazaki et al. (2014)
Ua Mit MT-ATP6/ATP SYNTHASE 6 - PM MIM516060 Mitochondrial ATP production Verny et al. (2011)
SPOAN 11q13 – – – MIM609541 Unknown Macedo-Souza et al. (2005)
BMP = bone morphogenic protein; del = deletion; dupl = duplication; ER = endoplasmic reticulum; ERAD = ER-associated degradation; indel = insertion/mutation; ins = insertion; Mit = mitochondrial; PM = point mutation;
PPF = protein putative function; TOM = type of mutation; ss = splice site mutation; Ua = unassigned SPGs.
a Loci from http://www.ncbi.nlm.nih.gov/omim/ (OMIM).
b Total exons, including UTR.
c Locus or gene discovery.













Inheritance and clinical features of HSP patients.
Type MI NOF Onset Phenotype Additional features
SPG1 X-linked ~20 EO C Mental retardation, aphasia, shufﬂing gait, and adducted thumbs, hydrocephalus, ACC
SPG2 X-linked ~10 VO P or C Seizures, mental retardation, nystagmus, ataxia, WMLs, PNP
SPG3A AD ~35 EO P or C Lower limb muscle atrophy, seizures, ataxia, OA, spasticity in the upper limbs, sensorimotor axonal PNP, CI,
cranial nerve impairment, intellectual disability, pes cavus, TCC
SPG4 AD ~130 VO P or C CI, epilepsy, ataxia, psychosis, upper limb spasticity, pes cavus, posterior fossa abnormalities, PNP, hand tremor,
WMLs, amyotrophy of small hand muscles
SPG5A AR ~35 VO P or C OA, WMLs, cerebellar ataxia
SPG6 AD 11 TO P or C IGE, dysarthria, PNP, CI, facial dystonia, atrophy of the small hand muscles, upper limbs spasticity, pes cavus
SPG7 AR ~30 VO P or C CS, cerebellar atrophy, PNP, OA, supranuclear palsy, CI of attention and executive functions, TCC, scoliosis,
pes cavus
SPG8 AD 10 AO P -
SPG9 AD 1 TO C Cataracts, motor PNP, skeletal abnormalities, gastrooesophageal reﬂux
SPG10 AD 17 EO P or C Distal amyotrophy in the upper extremities, CI, PNP, dysautonomia, parkinsonism, deafness,
retinitis pigmentosa
SPG11 AR ~35 VO C CS, PNP, WMLs, cerebellar atrophy, TCC, seizures, CI, abnormal eye signs, amyotrophy, parkinsonism,
maculopathy, action tremor, mental retardation, upper limbs weakness
SPG12 AD 4 EO P –
SPG13 AD 2 VO P or C Dystonia
SPG14 AR 1 AO C Motor PNP, mental retardation
SPG15 AR 20 EO C Pigmentary retinopathy, CS, PNP, amyotrophy, seizures, mental retardation, TCC
SPG16 X-linked 2 EO P or C Aphasia, ipovision, nystagmus, mental retardation
SPG17 AD 13 TO C Amyotrophy of small hand and feet muscles, lower motor neuron disease
SPG18 AR 3 EO C Epilepsy, mental retardation, congenital hip dislocation, multiple joint contractures
SPG19 AD 1 AO P -
SPG20 AR ~25 EO C Mental retardation, dysarthria, upper limbs spasticity, CS, euphoria, crying, WMLs
SPG21 AR 2 EO C Dementia, TCC, WMLs, CS, extrapyramidal features, callosal disconnection syndrome
SPG22 X-linked ~10 EO C Mental retardation, muscle atrophy, distal wasting, dyskinesia, nystagmus, ataxia
SPG23 AR 4 EO C CI, pigmentary abnormalities, facial and skeletal dysmorphism, tremor
SPG24 AR 1 EO C Pseudobulbar signs
SPG25 AR 1 AO C Cataracts, PNP, disc erniation
SPG26 AR 5 EO C Intellectual disability, cortical atrophy, PNP, distal atrophy. cerebellar ataxia, WMLs
SPG27 AR 2 VO C Dysarthria, mental retardation, PNP
SPG28 AR 3 EO P or C Saccadic eye pursuit, axonal PNP
SPG29 AD 1 TO C Pes cavus, hearing loss, hiatal hernia, hyperbilirubinaemia
SPG30 AR 3 TO P or C Sensory PNP, CS, hypoacusis, distal muscle wasting
SPG31 AD ~30 EO P or C PNP, cerebellar ataxia, tremor, dementia, amyotrophy of small hand muscles, pes cavus
SPG32 AR 1 EO C Mental retardation, pontine dysraphism, TCC
SPG33 AD 1 AO C Pes equinus
SPG34 X-linked 1 VO P –
SPG35 AR 2 EO P or C CI, epilepsy
SPG36 AD 1 VO C Sensory PNP
SPG37 AD 1 VO P -
SPG38 AD 1 VO C Amyotrophy of small hand muscles, PNP
SPG39 AR 2 EO C Distal wasting in upper limbs, axonal PNP
SPG40 AD 1 AO P or C Hyperrreﬂexia of upper limbs, CI
SPG41 AD 1 TO P -
SPG42 AD 1 VO P -
SPG43 AR 1 VO C Amyotrophy of small hand muscles, bilateral OA, axonal sensory and motor PNP, brain iron deposits in the
globus pallidus
SPG44 AR 1 AO C CI, CS, dysarthria, WMLs, pes cavus, TCC, scoliosis, upper limbs involvement
SPG45 AR 1 EO C Mental retardation, pendular nystagmus, OA
SPG46 AR 4 EO C Mental retardation, cataract, cerebellar atrophy, TCC, hypogonadism in males
SPG47 AR 2 EO C Periventricular WMLs, TCC, microcephaly, epilepsy, waddling gait, joint hyperlaxity
SPG48 AR 1 AO P or C Spinal cord hyperintensities
SPG49 AR 3 EO C Delayed psychomotor development, mental retardation, TCC, cerebral and cerebellar dysfunction, dysmorphic
features, central apnea
SPG50 AR 1 EO C Tetraplegic cerebral palsy, mental retardation, reduction of cerebral white matter, atrophy of the cerebellum
SPG51 AR 2 EO C Microcephaly, growth and intellectual retardation
SPG52 AR 1 EO C Delayed speech, stereotypic laughter, growth retardation
SPG53 AR 3 EO C Spasticity in upper extremities, delays in cognition and speech, kyphosis, pectus carinatum, hypertrichosis
SPG54 AR 6 EO C Mental retardation, strabismus, dysarthria, dysphagia, optic-nerve hypoplasia, short stature, TCC, laterally
deviated feet, abnormal lipid peak on brain spettroscopy, WMLs
SPG55 AR 1 EO C OA, PNP pes equinovarus
SPG56 AR 5 EO P or C TCC, CI, upper limbs involvement, basal-ganglia calciﬁcation. dystonic postures, WMLs
SPG57 AR 1 EO C OA, PNP
SPG58 AR 3 EO P or C Chorea, myoclonus, ataxia, hypodontia, deafness, short stature, pes planus, ptosis, developmental delay,
mental retardation, WMLs
SPG59 AR 1 EO C Nystagmus, borderline intelligence
SPG60 AR 1 EO C PNP in lower limbs, nystagmus
SPG61 AR 1 EO C Loss of terminal digits, acromutilation, PNP
SPG62 AR 3 EO P –
SPG63 AR 1 EO C TCC, WMLs, underweight, short stature
SPG64 AR 2 EO C Pes equinovarus, aggressiveness, delayed puberty, microcephaly, borderline intelligence
SPG65 AR 5 EO P or C TCC, defective myelination, small bilateral cystic occipital leukomalacia, learning disability, pes equinovarus
SPG66 AR 1 EO C Corpus callosum and cerebellar hypoplasia, colpocephaly, borderline intelligence, PNP, pes equinovarus
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Table 2 (continued)
Type MI NOF Onset Phenotype Additional features
SPG67 AR 1 EO C Distended abdomen, borderline intelligence, ACC, vermis hypoplasia, defective myelination
SPG68 AR 1 EO C Nystagmus, OA, PNP, amyotrophy, foot drop
SPG69 AR 1 EO C Intellectual disability, deafness, cataract
SPG70 AR 1 EO C Scoliosis, bilateral Achilles contracture, borderline intelligence, nephrotic syndrome
SPG71 AR 1 EO C TCC
SPG72 AD and AR 3 EO P -
GAD1 gene AR 1 EO C Spastic cerebral palsy, mental retardation
Cct5 gene AR 1 EO C Mutilating sensory neuropathy
OPA3 gene AR 1 EO C OA, chorea, cerebellar ataxia, dementia
BICD2 gene AR 1 EO P -
MAG gene AR 1 EO C Nystagmus, poor school achievement
LYST gene AR 1 AO C PNP, cerebellar ataxia
ATPase6 gene Maternal 1 AO C Diabetes mellitus, hypertrophic cardiomyopathy, supraventricular arrhythmia, cerebellar syndrome
SPOAN AR 2 EO C OA, PNP, dysarthria, exacerbated acoustic startle response, joint retractions, spine deformities, ﬁxation
nystagmus, distal amyotrophy, extrapiramidal signs
ACC = agenesis corpus callosum; AO = adult onset; AD = autosomal dominant; AR = autosomal recessive; C = complicated; CI = cognitive impairment; CS = cerebellar signs;
EO = early onset (infancy); IGE = idiopathic generalized epilepsy; MI = mode of inheritance; NOF = number of families; OA = optic atrophy; P = pure; PNP = polyneuropathy;
TCC = thin corpus callosum; TO = teenage onset; VO = variable onset (infancy, teenage, or adult); WMLs = white matter lesions.
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CoA, caused by a reduced ﬂow of acetyl-CoA into the Golgi apparatus, can
result in misprocessing of gangliosides and glycoproteins.
A single, large Chinese family, harboring the missense p. S113R, has
been reported with a possible loss of function (Lin et al., 2008).
SPG72
In affectedmembers of a large French familywithADHSP, it has been
identiﬁed a heterozygous missense mutation in the REEP2 gene
(Esteves et al., 2014) (Tables 1 and 2).
ARHSP
Forty-eight SPG loci and 41 genes responsible for ARHSP have been
identiﬁed so far. Several other ARHSP loci, namely SPG14 (Vazza et al.,
2000), SPG23 (Blumen et al., 2003), SPG24 (Hodgkinson et al., 2002),
SPG25 (Zortea et al., 2002), SPG27 (Meijer et al., 2004; Ribaï et al.,
2006), SPG32 (Stevanin et al., 2007a), and SPG45 (Dursun et al., 2009),
have been identiﬁed but pathological genes are yet unknown (Tables 1
and 2).
SPG5A
SPG5A/CYB7B1 encodes cytochrome P450 oxysterol 7-hydroxylase,
implicated in biosynthesis, storage and catabolism of brain cholesterol
metabolites. The gene product of CYP7B1 also participates in the “acidic”
pathway of bile acid synthesis (Arnoldi et al., 2012). The role of 27-
hydroxy-cholesterol blood accumulation in SPG5A-patients, its role as
pathogenetic player and its utility in clinical practice is still debated
(Schüle et al., 2010).
More than 20 different mutations were reported (Goizet et al.,
2009a; Schüle et al., 2009b; Tsaousidou et al., 2008). Pure form is the
most common; periventricular and subcortical white matter lesions
(WMLs) are observed in many patients (Biancheri et al., 2009).
Electrophysiological investigations revealed pathologic motor evoked
potentials (MEPs), sensory evoked potentials (SEPs), visual evoked po-
tentials (VEPs), and auditory evoked potentials (AEPs), in contrast with
normal nerve conduction study and EMG (Manganelli et al., 2011).
SPG7
SPG7/PGN encodes paraplegin, one of the proteins forming the m-
AAA protease complex located in the mitochondrial membrane. This
protein is constituted by two peptide regions, a metallo-peptidase do-
main and an ATPase domain (reviewed in Langer, 2000). PGN variants
identiﬁed to date are almost all nonsense loss-of-function mutations
or missense mutations in the metallo-peptidase domain (Casari et al.,1998); however, some mutations cause an amino acid substitution
mapping in the AAA-domain. Paraplegin is involved in the removal of
damaged or misfolded proteins, the proteolytic activation of essential
mitochondrial proteins and ribosome maturation; ultrastructural stud-
ies showed abnormal shaping of mitochondria (Nolden et al., 2005).
Patients may show cerebellar signs or cerebellar atrophy (Brugman
et al., 2008; Elleuch et al., 2006) that, in addition to optic neuropathy
(or abnormalities on optical coherence tomography), are key features
for the diagnosis of SPG7 (Klebe et al., 2012b).
SPG11
SPG11/KIAA1840mutations are the most common cause of ARHSP
(Stevanin et al., 2007b, 2008). Genetic analyses of KIAA1840 revealed
several types of mutations leading to protein loss of function. Recent
identiﬁcation of repeated Alu elements should be linked to SPG11
locus instability, making this genomic region prone to large gene rear-
rangements (Conceição Pereira et al., 2012). KIAA1840, encoding
spatacsin, is expressed ubiquitously in the nervous system, but most
prominently in the cerebellum, cerebral cortex, hippocampus and pine-
al gland. The speciﬁc role of peptide remains unknown, though it seems
to be essential to the survival of neurons (Crimella et al., 2009;
Southgate et al., 2010).
KIAA1840mutations have been identiﬁed as a genetic cause of juve-
nile amyotrophic lateral sclerosis type 5 (ALS5) in 40% of patients
(Orlacchio et al., 2010) and Kjellin syndrome (Orlén et al., 2009) charac-
terized by central retinal degeneration, mental retardation and
amyotrophy in addition to ARHSP-TCC.
On average, patients become wheelchair-bound 16 years after
disease onset. Cognitive impairment and TCC are reliable phenotype
predictors of SPG11; other common features are axonal polyneuropathy
and cerebellar signs (Del Bo et al., 2007; Pippucci et al., 2009; Stevanin
et al., 2006). Hehr et al. (2007) hypothesized that phenotype results
from the combined degeneration of central and peripheral axons and
neuronal loss within cortical and thalamic regions and in the spinal
cord.
SPG15
Patients carrying mutations in SPG15/ZFYVE26, encoding spastizin,
show similar symptoms to those observed in SPG11 (Table 2). Mutations
lead to loss of protein ormutated forms of proteinwith defective autoph-
agy (Vantaggiato et al., 2013).
Originally mapped in families with Kjellin syndrome (Hanein et al.,
2008; Kjellin, 1959), SPG15 is the second most common cause of HSP-
TCC (Goizet et al., 2009b). Being relatively rarer than SPG11, genetic
test is recommended in SPG11 negative patients only.
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ERLIN2 in the SPG18 locus encodes SPFH2 protein that contains a
characteristic SPFH (stomatin–prohibitin–ﬂotillin–HﬂC/K) domain.
This peptidic region makes the protein capable of assembling into an
oligomeric structure anchored to the cellular membrane. SPFH2 has
been shown to regulate the ER-associated degradation (ERAD) pathway
by interacting with endogenous proteins and resulting in their
polyubiquitination and proteasome degradation (Pearce et al., 2007).
Three loss-of-function mutations in ERLIN2 have been reported in
families from Saudi Arabia (Alazami et al., 2011; Wakil et al., 2013;
Yildirim et al., 2011). Patients carrying a nullimorphic ERLIN2mutation
showed additional features of mental retardation, late epilepsy and hip
dislocation (Alazami et al., 2011).
SPG20
Troyer syndrome is a complicated ARHSP that occurs with high fre-
quency in Amish people and it was also reported in two Omani families:
a frameshift mutation due to a single base deletion producing a truncat-
ed SPG20/spartin protein and two null mutations were reported in
SPG20 (Bakowska et al., 2008; Manzini et al., 2010; Patel et al., 2002).
The encoded protein, spartin, has been considered as a multifunctional
protein, playing a role in protein folding and turnover, both in mito-
chondria and ER. It seems to have a crucial function in the ubiquitination
and degradation of lipid droplet-associated proteins (Milewska et al.,
2009). Spartin contains several distinct domains including an N-
terminal MIT region, which is responsible for its interactionwithmicro-
tubule and trafﬁcking molecules (Ciccarelli et al., 2003).
Troyer syndrome is characterized by mental retardation, distal
muscle wasting, dysarthria, and quadriparesis. Cerebellar signs,
choreoathetosis, euphoria, crying, and WMLs on brain MRI may
also be observed (Proukakis et al., 2004).
SPG21
Mast syndrome, initially described by Cross andMcKusick (1967), is
a complicated form of ARHSP associated with dementia and other CNS
abnormalities, that is present at high frequency among the Old Order
Amish. It is caused by SPG21/ACP33mutations. The single base-pair in-
sertion reported in anAmishpedigree results in the premature termina-
tion of the encoded product maspardin. This protein has been shown to
localize in vesicle of the endosomal/trans-Golgi network, highlighting a
possible role of this protein in cellular transport and sorting, and its role
in neuronal cells has been conﬁrmed in SPG21−/−knockoutmice, which
also showed alterations in axon branching (Soderblom et al., 2010).
SPG21-patients, in addition to slowly progressive pure phenotype
that develops in early adulthood, may show cerebellar and extrapyra-
midal signs in the advanced disease. Most of patients have TCC and
WMLs on MRI (Simpson et al., 2003). Recently, a missense mutation
(p.A108P) in APC33 was identiﬁed in a Japanese family (Ishiura et al.,
2014).
SPG26
SPG26/B4GALNT1 encodes β-1,4-N-acetyl-galactosaminyl transfer-
ase 1, involved in ganglioside biosynthesis. Gangliosides belong to the
family of glycosphingolipids, which are components of the synaptic
plasma involved in synaptic plasticity, signal transduction, and endocy-
tosis. B4GALNT1 catalyzes the transfer of N-acetyl-galactosamine into
GM3, GD3, and globotriaosylceramide by a β-1,4 linkage. The reverse
reaction is performed by β-hexosaminidase and its cofactor (GM2 acti-
vator). Molecular defects in the degradation of glycosphingolipids lead
to lysosomal storage diseases.
Truncating, missense mutations, and deletions of B4GALNT1 cause
complicated early onset ARHSP (Boukhris et al., 2013). It is worthy of
note that SPG26 is the second disorder of ganglioside biosynthesis
after SPG46 (Martin et al., 2013). These ﬁndings conﬁrm the increasing
interest of lipid metabolism in HSP.Patients carrying the B4GALNT1 mutation had an early onset (2 to
19 years) spastic paraplegia with intellectual impairment. About a
third of such patients also had mild upper limb involvement. Other fea-
tures were more variable (Boukhris et al., 2013).
SPG28
Truncating mutations in SPG28/DDHD1, encoding PAPLA1 (phos-
phatidic-acid-preferring phospholipase A1), are reported in pure and
complicated HSP.
PAPLA1 is involved in the maintenance of the ER and Golgi struc-
tures. DDHD1mutations also cause mitochondrial dysfunction, includ-
ing reduced respiration and ATP production that might result from the
accumulation of PA in mitochondria. Therefore, DDHD1 might also be
involved in similar functions in the maintenance of organelle mem-
branes and intracellular trafﬁcking (Higgs et al., 1998; Nakajima et al.,
2002; Tani et al., 1999).
The discovery of DDHD1 mutations in three additional SPG28-
affected subjects extended the clinical spectrum of this disease,
compared to the pure phenotype originally described in a singleMoroc-
can family (Bouslam et al., 2005; Tesson et al., 2012).
SPG30
SPG30/KIF1A encodes the kinesin 3 protein. The protein belongs to
the kinesin-3 family that is involved in intracellular anterograde trans-
port of dense core vesicles (DCVs), containing neuropeptide cargos,
along microtubules to the pre- and post-synaptical cellular regions:
gene deletion determines a reduction of DCVs at synapses, followed
by an accumulation of such vesicles in the cell body and neuronal
death (Lo et al., 2011).
Missense mutations have been reported (Erlich et al., 2011; Klebe
et al., 2012a), causing early onset and slow progressive HSP. Nonsense
mutations in the same gene cause hereditary sensory neuropathy type
IIC (HSN2C) (Rivière et al., 2011).
SPG35
FA2H enzyme catalyzes the synthesis of sphingolipids containing 2-
hydroxy fatty acids; these biochemical compounds participate in sever-
al biological processes. In particular, SPG35/FA2H null mice suggested
that the protein is necessary in long-term maintenance of myelin
(Zöller et al., 2008).
SPG35 is generally characterized by childhood onset of gait difﬁcul-
ties, dysarthria, cognitive impairment, and leukodystrophy on MRI
(Dick et al., 2010). FA2Hmutations are involved in other two neurode-
generative diseases: leukodystrophy with spastic paraparesis and
dystonia (Edvardson et al., 2008) and neurodegeneration with brain
iron accumulation (NBIA). Kruer et al. (2010) referred to this phenotyp-
ic spectrum of disorders as fatty acid hydroxylase associated neurode-
generation (FAHN).
SPG39
The gene at the SPG39 locus has been identiﬁed in a novel HSP, des-
ignated NTE-related motor neuron disease (NTE-MND) (Rainier et al.,
2008): it is the neuropathy target esterase gene (NTE), encoding
PNPLA6. The protein plays a role in axonopathy produced by organo-
phosphorus compounds; moreover, knockdown experiments show
that it is also implicated in survival of developing embryos (Moser
et al., 2004).
Reported point mutations, disrupting the catalytic domain, decrease
hydrolysis activities and alter the ability to be reactivated by nucleo-
philes (Hein et al., 2010). An insertion mutation, causing frameshift
and protein truncation, is also reported in compound heterozygosity
(Synofzik et al., 2014).
The affected phenotype in each family conformed both to organo-
phosphorus compound-induced delayed neuropathy (OPIDN) and to
Troyer-like syndrome. In childhood, patients exhibit features of the
pure form later associated with wasting of distal leg and intrinsic hand
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axonopathy affecting upper and lower limbs. Single SPG39-patient
showed atrophy of the spinal cord, particularly in the thoracic region
on MRI (Rainier et al., 2008).
SPG43
SPG43, previously described in two Malian sisters (Meilleur et al.,
2010), is caused by missense mutation or nucleotides deletion in
C19orf12 (Landouré et al., 2013).Mutations in the same gene are also re-
ported in a series of patients with NBIA (Hartig et al., 2011).
In addition to Silver syndrome, patients may have bilateral optic at-
rophy or axonal sensorymotor polyneuropathy andMRI evidenced iron
deposits in the globus pallidus of Brazilian patients, linking with SPG43
and NBIA (Landouré et al., 2013).
SPG44
SPG44 is caused by a homozygous point mutation in GJC2,
encoding connexin-47 (Orthmann-Murphy et al., 2009). Recessive
mutations in this gene also cause Pelizaeus–Merzbacher-like disease
(PMLD), which is characterized by severe CNS demyelination
(Orthmann-Murphy et al., 2007). Connexin-47 is constituted by
four transmembrane, two extracellular, and three cytoplasmic
domains. This protein belongs to the connexin family and it forms
gap junctions (intercellular channels), allowing direct cell-to-cell
diffusion of ions and small molecules.
SPG44-related patients (threemembers of a large Italian family) had
pes cavus and a late onset slowly progressive paraplegia. Brain MRI
showed a hypomyelinating leukodystrophy and TCC in all three
patients. Other features in individual patients include dysarthria, loss
of ﬁnger dexterity, dysmetria, intention tremor, scoliosis, upper limb
involvement, and cognitive impairment (Orthmann-Murphy et al.,
2009).
SPG46
Four differentmutations inGBA2 (glucosidase beta bile acid 2), three
truncating variants, and one missense variant, were identiﬁed in four
unrelated SPG46 families (Martin et al., 2013). This is a complicated
form with slowly progressive spastic paraplegia and cerebellar signs.
Some patients show cerebral and cerebellar atrophy and TCC on brain
MRI (Boukhris et al., 2008, 2010; Martin et al., 2013). Homozygous mu-
tations in GBA2 were also found in patients with autosomal recessive
cerebellar ataxia and spasticity (Hammer et al., 2013).
GBA2 encodes a microsomal non-lysosomal glucosylceramidase, lo-
calized in the endoplasmic reticulum and at the cell surface, which cat-
alyzes the conversion of glucosylceramide to free glucose and ceramide
and the hydrolysis of bile acid 3-O-glucosides. Ceramides formed by this
enzyme are rapidly converted into sphingomyelin (Yildiz et al., 2006).
Themissense variant was also found at the homozygous state in a single
patient, in whom no residual glucocerebrosidase activity of GBA2 was
proven in blood cells, opening the way to a possible measurement of
this enzyme activity in clinical practice (Martin et al., 2013).
SPG47, SPG50–SPG52
These neurodegenerative disorders are characterized by neonatal
hypotonia of all limbs that progresses to spasticity and severemental re-
tardation with poor or absent speech development (Abou Jamra et al.,
2011).
Mutations in genes encoding heterotetrameric adaptor protein 4
complex (AP4) subunits were identiﬁed: a frameshift mutation (Abou
Jamra et al., 2011) and a truncating mutation (Bauer et al., 2012) in
SPG47/AP4B1, a splice mutation in SPG51/AP4E1 (Abou Jamra et al.,
2011) and a nonsense mutation in SPG52/AP4S1 (Abou Jamra et al.,
2011). Two mutations affecting SPG50/AP4M1 and AP4E1 have recently
been found to cause cerebral palsy associated with severe intellectual
disability (Verkerk et al., 2009).Moreno-De-Luca et al. (2011) proposed the designation of ‘AP4 de-
ﬁciency syndrome’ to refer to disorders caused by disruption of any of
the four AP4 subunits.
SPG48
An insertion/deletion has been found in SPG48/KIAA0415 in twoHSP
siblings; KIAA0415 encodes a putative helicase (AP5Z1), with both nu-
clear and cytoplasmic localization, involved in DNA double-strand
break repair processes and known to be a spatacsin and spastizin
interactor. In particular, spatacsin is phosphorylated upon DNA damage
by protein kinases ATM (ataxia telangiectasia mutated) or ATR (ATM
and Rad3-related) (Słabicki et al., 2010). A recent study showed that
the protein is a member of the adaptor protein 5 complex (AP5) that
is implicated in vesicle formation and sorting (as AP4) (Hirst et al.,
2011).
The two siblings, in the single French family reported, presented
spastic paraplegia associated with urinary incontinence. One had spinal
hyperintensities on MRI in the cervical spine. The unaffected parents
were from two neighboring villages (Słabicki et al., 2010).
SPG49
Oz-Levi et al. (2012) identiﬁed a homozygous truncating mutation
in SPG49/TECPR2 (tectonin beta-propeller repeat containing 2) in a
form of complicated HSP. This HSP is characterized by onset of spastic
paraplegia in theﬁrst decade, delayed psychomotor development,men-
tal retardation, dysmorphic features (such as short stature,mild brachy-
cephalic microcephaly, round face, low anterior hairline, dental
crowding, short broad neck, a chubby appearance), dysarthria,
dysmetria, TCC on brain imaging and episodes of central apnea.
SPG53
A homozygous mutation in SPG53/VPS37A (vacuolar protein sorting
37A), a member of the endosomal sorting complex required for trans-
port (ESCRT) system, has been described in a complicated HSP
(Zivony-Elboum et al., 2012). The system plays a central role in intracel-
lular trafﬁcking, maturation of multivesicular bodies, and sorting of
ubiquitinated membrane proteins into internal luminal vesicles
(Raiborg and Stenmark, 2009).
Disease progresses from onset in infancy of delayed motor develop-
ment to upper and lower limb spasticity. Affected individuals also show
mild to moderate cognitive and speech delay.
SPG54
Biallelic or homozygous frameshift and missense mutations of
SPG54/DDHD2 were identiﬁed in a complicated early onset HSP
(Schuurs-Hoeijmakers et al., 2012).
The DDHD2 protein belongs to the mammalian intracellular phos-
pholipase A1, implicated in organelle biogenesis andmembrane trafﬁck-
ing. DDHD2 preferentially hydrolyzes phosphatidic acid but also
exhibits activity toward phosphatidylethanolamine. RNA-interference
experiments in cellular systems indicated a role of DDHD2 in transport
from the Golgi to the plasmamembrane. In view of this, it was hypoth-
esized that DDHD2 facilitatesmembrane and vesicle fusion by themod-
iﬁcation of membranes through phospholipid hydrolysis (Inoue et al.,
2012; Morikawa et al., 2009; Nakajima et al., 2002; Sato et al., 2010;
Tani et al., 1999).
Phenotype among all six families was relatively homogeneous
(Table 2) with mental retardation and early onset of progressive spas-
ticity before the age of 2 years. In line with the function in lipid metab-
olism, an abnormal lipid peak indicating accumulation of lipids was
detected with cerebral magnetic resonance spectroscopy (MRS) with
the highest intensity around the basal ganglia and thalamus. This can
be an applicable diagnostic biomarker to distinguish the SPG54 pheno-
type from other complicated HSP (Schuurs-Hoeijmakers et al., 2012).
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A nonsense mutation in SPG55/C12orf65 was identiﬁed in two pa-
tients with HSP complicated by optic atrophy and polyneuropathy in a
Japanese family (Shimazaki et al., 2012).
The C12ORF65 protein belongs to the mitochondrial class I peptide
release factors. Its function is still not clear. It might play a role in
recycling abortive peptidyl-tRNAs that were prematurely released
from ribosomes during polypeptide elongation (Antonicka et al., 2010;
Richter et al., 2010). This mutation causes marked reduction of mito-
chondrial protein synthesis, followed by functional and structural de-
fects in respiratory complexes I and IV. A study in cultured neurons
showed that complex I deﬁciency could increasemitochondrial reactive
oxygen species leading to neuronal death (Abramov andDuchen, 2010).
SPG56
CYP2U1 is a cytochrome P450 protein implicated in ω- and ω−1
fatty-acid (C16–C22) hydroxylation. CYP2U1 is able to catalyze the hy-
droxylation of arachidonic acid and related long-chain fatty acids such
as eicosapentaenoic and docosahexaenoic acids. Two known metabo-
lites, 19- and 20-hydroxyeicosatetraenoic acids, are local mediators of
signal transduction (Carroll and McGiff, 2000; Chuang et al., 2004).
Missense and deletion mutations in SPG56/CYP2U1 are reported in
ﬁve unrelated families with ARHSP (Tesson et al., 2012). Affected indi-
viduals developed spastic paraplegia with a range from birth to
8 years. Symptom severity varied widely: complicated phenotype
includes upper limbs involvement, dystonic posturing of the upper
limbs, mental retardation, subclinical axonal polyneuropathy, WMLs
on brain MRI, calciﬁcations in the globus pallidus and TCC (Citterio
et al., 2014).
SPG57
In two siblings with early onset spastic paraplegia, optic atrophy,
and polyneuropathy, a genetic analysis revealed a homozygous var-
iant, p.R106C, in Trk-fused (TFG) as the only plausible mutation
(Beetz et al., 2013). Intriguingly, a heterozygous mutation, p.P285L,
was demonstrated in a distinct phenotype called hereditary motor and
sensory neuropathy with proximal dominant involvement (HMSN-P)
(Ishiura et al., 2012).
Native TFG functions affect vesicle biogenesis on the ER, the forma-
tion of a matrix between ER exit sites and the ER–Golgi intermediate
compartment, a sorting hub for secretory cargoes in metazoan cells
(Witte et al., 2011). Mutant protein lacks its ability to self-assemble
into an oligomeric complex, which is a critical phase for normal TFG
function. In cell lines, TFG inhibition slows protein secretion from the
ER and alters ER morphology, disrupting organization of peripheral ER
tubules and causing collapse of the ER network onto the underlyingmi-
crotubule cytoskeleton (Beetz et al., 2013).
SPG58–SPG72
Very recently, 15 candidate genes for ARHSP were reported and the
assigned locus for HSP increased up to SPG72 (Esteves et al., 2014;
Novarino et al., 2014) (Fig. 2, Tables 1 and 2). Based on the putative bi-
ological function,most of these genes can be stratiﬁed into the function-
al modules described below.
XLHSP
To date, ﬁve X-linked SPG loci, named SPG1, SPG2, SPG16, SPG22,
and SPG34, and three genes (L1CAM, PLP1, and SLC16A2) have been
identiﬁed. Gene identity at the SPG16 (Steinmuller et al., 1997) and
SPG34 (Macedo-Souza et al., 2008) loci are unknown (details in
Tables 1 and 2).
SPG1
X-linked hydrocephalus, MASA (mental retardation, aphasia, shuf-
ﬂing gait, and adducted thumbs) syndrome, X-linked complicatedSPG1 and X-linked partial agenesis of the corpus callosum are the four
diseases usually referred to L1 syndrome, caused by mutations in
SPG1/L1CAM (Jouet et al., 1994). Its product (NCAM) is a transmem-
brane glycoprotein mainly expressed in neurons and Schwann cells.
SPG2
SPG2 is caused by mutations in PLP1 (proteolipid protein 1),
encoding myelin proteolipid protein (MPLP), the major myelin
protein responsible for stabilization and maintenance of the
myelin sheath. PLP1 variants also lead to Pelizaeus–Merzbacher
disease, a hypomyelination disorder having onset in infancy and
death in young adulthood (Saugier-Veber et al., 1994). Several
mutations in PLP1 have been identiﬁed ranging from entire gene duplica-
tions, deletions, and intragenic sequence variants (Cailloux et al., 2000).
Only males are affected, exhibiting slowly progressive paraplegia;
some patients have nystagmus, ataxia, cerebral or spinal WMLs,
polyneuropathy, and, in a single case, dementia (Suzuki et al., 2011).
SPG22
This HSP is caused bymutations in SPG22/SLC16A2 encodingmono-
carboxylate transporter 8 (MCT8) (Schwartz et al., 2005). The protein is
essential in triiodothyronine transport into neurons, and contributes to
axon pathﬁnding (reviewed in Blackstone et al., 2011); its abnormal
function is reﬂected in elevated free triiodothyronine and lowered free
thyroxine levels in the blood (Friesema et al., 2003).
Clinical manifestations in complex form (Allan–Herndon–Dudley
syndrome) include severe mental retardation, dysarthria, athetoid
movements, muscle hypoplasia, and spastic paraplegia (Boccone et al.,
2010; Schwartz et al., 2005).
Unassigned SPGs
GAD1 gene
A homozygous nonsense mutation in glutamic acid decarboxylase
1(GAD1) leading to a protein truncation has been identiﬁed in patients
from consanguineous Pakistan families; affected subjects had cerebral
palsy and mental retardation (Lynex et al., 2004).
GAD1 encodes for the 67 kDa isoform of L-glutamate decarboxylase
(GAD67), which is involved in conversion of the excitatory neurotrans-
mitter glutamate to the inhibitory neurotransmitter GABA. The gluta-
matergic excitotoxicity may play a role in this context too.
Cct5 gene
Cct5 encodes the epsilon subunit of the cytosolic chaperonin-
containing t-complex peptide-1 (CCT): a homozygous missense muta-
tion p.H147Rwas identiﬁed in this gene in four patients from a consan-
guineous Moroccan family, displaying mutilating sensory neuropathy
associated with spastic paraplegia (Bouhouche et al., 2006).
Molecular chaperones play an important role in the folding of many
proteins and the CCT complex is a member of the two major chaperone
systems that promote folding and assembly of awider range of cytosolic
substrates (actin and tubulin in particular).
OPA3 gene
Mutations in this gene cause 3-methylglutaconic aciduria type III
(Costeff optic atrophy syndrome) (Anikster et al., 2001) and autosomal
dominant optic atrophy and cataract (Reynier et al., 2004). In a recent
study, two cousins from consanguineous parents showed, in addition
to optic atrophy,motor symptoms from the age of 3 to 4 years including
chorea, cerebellar ataxia, dystonia, and pyramidal tract signs of lower
limbs. Exome sequencing revealed 2 homozygous variants (c.32 TNA
[p.L11Q] in OPA3 and c.941 CNG [p.A314G] in TSHZ3) that segregated
with the disease. Only the OPA3 variant was absent in the control sub-
jects and predicted to be damaging (Arif et al., 2013).
Fig. 2.HSPproteins involved in cellular functionsdivided intomajor functionalmodules. (A) Paraplegin (m-AAAprotein) andHSP60 control the removal of damagedormisfolded proteins
in mitochondria, respectively; TIM (translocase of the inner membrane) and TOM (translocase of the outer membrane) are mitochondrial membrane transporters for mitochondria-
destined proteins. (B) In the axonal transport, spastin is responsible for the disassembly of microtubules acting on the kinesin HC5A and kinesin 3 function in the transport of anterograde
cargoes. (C) Proteins implicated in synthesis, metabolism, and distribution of lipids and sterols; ACoA carrier carries acetyl-CoA into the lumen of Golgi apparatus and then it is transferred
to the sialyl residues of gangliosides and glycoproteins. (D) AP5Z1 is implicated in DNA double-strand break repair. The other proteins are involved in nucleotide metabolism. (E) MPLP,
connexin (Cx) 47, FA2H, and MAG are involved in the stabilization and maintenance of the myelin sheath. (F) KIAA0329 and spastizin participate in the degradation of unnecessary or
dysfunctional cellular components through the actions of lysosomes (autophagy). (G) Proteins involved in axon development. (H) Other proteins, such as NIPA1 and AP4 subunits, are
involved in the endosomal pathway. (I) The ERAD pathway is regulated by ERLIN1 and SPFH2. Proteins involved in protein folding are in the left of the box. (J) Reticulon-2, spastin,
REEP1, and REEP2 are involved in membrane modeling and shaping by interacting each other. In synaptic terminals, GAD1 converts glutamic acid (Glu) into GABA; LYST is a lysosomal
trafﬁcking regulator (circles in turquoise).
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namics and respiratory chain complex protein stability (Grau et al.,
2013).
BICD2, MAG, and LYST genes
These three genes were lately found mutated in ARHSP patients
(Novarino et al., 2014; Shimazaki et al., 2014) (Fig. 2, Tables 1 and
2).
HSP with maternal inheritance
A late onset HSP due to m.9176 TNCmtDNAmutation inMT-ATP6 in
ﬁve members of a large family is the ﬁrst and sole maternally-inherited
form of HSP described to date (Verny et al., 2011). Variable clinical pre-
sentation is the hallmark of mtDNA mutations: for example, like the
more common m.8993 TNG, the m.9176 TNC change is associated with
the severe neonatal-onset Leigh syndrome (Dionisi-Vici et al., 1998;
Hung and Wang, 2007).
Phenotypic variability (Table 2) in this family cannot be explained by
the mutant load, and other factors (nuclear modifying genes or themtDNA background) may be involved in the phenotypic expression of
the disease. Moreover, three additional mitochondrial encoded genes
have been identiﬁed in HSP (PGN, HSPD1, and OPA3), focusing on the
importance of mitochondrial dysfunction (reviewed in Salinas et al.,
2008).
Other phenotypes
SPOAN syndrome (complicated spastic paraplegia associated with
optic atrophy and neuropathy) linked to 11q13 (Macedo-Souza et al.,
2005), a complex phenotype in a Japanese family (Hattori et al., 2010),
and a complex HSP related to oligodendropathy (Woehrer et al., 2012)
await molecular deﬁnition.
Functional modules
HSP is characterized by clinical and genetic heterogeneity, caused by
a large number of loci/genes involved. Proteins implicated in the onset
of the disease are part of speciﬁcmolecular pathways or perform similar
functions and the same protein can be implicated in several functions.
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are also presumed to create interactome networks (Novarino et al.,
2014).
Oxidative stress in HSP pathogenesis
PGNmutations determine the lack of the paraplegin/AFG3L2 com-
plex, responsible for a speciﬁc quality control of proteins that are local-
ized in the inner mitochondrial membrane; moreover, this complex is
also involved in a chaperone-like activity on the OXPHOS (oxidative
phosphorylation pathway) protein complexes (Maltecca et al., 2009).
The impairment in complex I activity has been observed in SPG7 sub-
jects and an increased sensitivity to oxidative stress has beenmeasured
in their ﬁbroblasts (reviewed in Rugarli and Langer, 2006). Paraplegin-
deﬁcient mice showed axonal degeneration with an abnormal mito-
chondrial morphology and impairment in axonal transport
(Ferreirinha et al., 2004), indicating a role for paraplegin in axon main-
tenance. A recent work has underlined the crucial role of both AFG3L2
and paraplegin in preventing neuronal death and, in particular, their
ability to inhibit cerebellar degeneration (Martinelli et al., 2009).
HSP60 functions only in combination with HSP10, forming a barrel-
like structure. Compared to controls, no particular mitochondrial
dysfunction has been observed in SPG13-patients; however, it has
been demonstrated that their cells show a decreased expression of
two quality control mitochondrial proteases Lon and ClpP (Hansen
et al., 2008). Instead, an abnormal functioning of mitochondrial respira-
tory chain complex I and IV has been found in a patient carrying a
mutation in REEP1 (Hewamadduma et al., 2009).
MT-ATP6 encodes a subunit of ATP synthase (Complex V). It leads to
complex V instability, impaired assembly, and function. Phenotypic
similarity has been observed between patients carrying mitochondrial
DNA (mtDNA) mutations and
HSP patients. On the basis of these observations, a recent work eval-
uated the possible involvement of common mitochondrial polymor-
phisms/haplogroups on the risk of developing HSP (Sánchez-Ferrero
et al., 2011).
Dysfunction of axonal transport
Axonal transport is believed to be primarily impaired in several HSP
forms. Well-characterized proteins will be focused on: spastin, kinesin
HC5A, and kinesin 3.
Spastin has a complex subcellular localization based on its differ-
ent isoforms (Lumb et al., 2012). The full-length isoform is mainly lo-
calized on the early secretory pathway, at the ER and probably also at
the very early ER-to-Golgi intermediate compartment. In contrast,
the isoform that lacks the ﬁrst 87 amino acids stretch exists in a cy-
tosolic pool and can be recruited to endosomes and to the cytokinetic
midbody during cell division. This isoform has also been described in
the nucleus due to two nuclear localization signals. While the wild-
type over-expressed form of spastin causes disassembly of microtu-
bules, the mutated form localizes with them (Errico et al., 2002).
With reference to the disassembly of microtubules, the spastin
seems to act in a hexameric form that binds polymerized tubulin
and induces a conformational change responsible for breaking mi-
crotubules. A recent work has described a post-translational
glutamylation of tubulin (the generation of long glutamate side
chains) that is a necessary step for spastin-dependent microtubule
disassembly (Lacroix et al., 2010). The spastin MIT domain also me-
diates the interaction with the charged multi vesicular body pro-
teins. These proteins form a complex named ESCRT-III, involved in
viral budding, formation, and sorting of cargoes into the late
endosomes, as well as in the resolution of the midbody membrane
(Raiborg and Stenmark, 2009). Spastin also interacts with protrudin.
The lack of protrudin in cultured neurons inhibits neurite extension,
whereas its over-expression promotes neurite extension (Shiraneand Nakayama, 2006). Moreover, a loss of spastin is suggested to re-
duce the rate of axonal branching in cultured primary neurons
(Riano et al., 2009). Post mortem analysis of SPG4 reported abnor-
malities in the distribution of mitochondria in spinal motor neurons,
emphasizing the spastin involvement in organelles axonal move-
ment (McDermott et al., 2003).
In mammals, kinesin HC5A is necessary for anterograde axonal
transport of neuroﬁlament subunits and it plays a role in the transport
of other anterograde cargoes, for example membrane vesicles (Reid
et al., 2002). Experimental data suggested that when KIF5A is mutated,
cargo transport to the distal axon is slowed, or microtubules binding
afﬁnity is decreased. Consequently, the frequency of anterograde
transport is lowered, and the arrival of the cargo to the synapse is largely
delayed. Alternatively, axonal degeneration in patients with HSP sub-
types may be caused by impaired slow axonal transport. Indeed, the
lack of neuroﬁlament supply to the synapsis is a plausible reason for
neurodegeneration (Ebbing et al., 2008).
Kinesin 3 is a highly processive and fast motor protein belonging to
the homonymous family ofmicrotubule-associated proteins involved in
intracellular transport (Lo et al., 2011). It is responsible for fast axonal
transport of DCVs, implicated in carrying organelles in neurons respon-
sible for transporting and secreting neuropeptides, but it remains asso-
ciated with them during retrograde axonal transport too. This protein
contains multiple protein–protein interaction domains that facilitate
differential cargo binding. Additionally, Park et al. (2008) demonstrated
that the complex containingdynactin–kinesin 2/kinesin 3 interactswith
carboxypeptidase E, which plays an important role in the transport of
pituitary hormones vesicles; yet, the exact mechanism of binding to
DCVs is not known.
Abnormal lipid metabolism
Someproteins involved in HSP play a role in lipidmetabolism at var-
ious levels.
CYP7B1 is one of two CYP7 family members, which is expressed in
several tissues (liver, kidney, and brain) (Siam et al., 2012). In the
brain, this hydroxylase is implicated in steroid hormone metabolism,
acting toward twoneurosteroids, pregnenolone and dehydroepiandros-
terone (DHEA), (Lorbek et al., 2012). CYP7B1 is also important for the 7-
hydroxylation of DHEA-related hydroxysteroids. Some data suggest
that this group of neurosteroids act as neuroprotective factors and
they can reduce ischemia-induced neurodegeneration. Consequently,
neurodegeneration associated with CYP7B1 mutation may also be
associated with a loss of neuroprotective function of DHEA-related
neurosteroids (Arnoldi et al., 2012).
PNPLA6 is a phospholipase/lysophospholipase and its activity
may be regulated by cAMP. The protein participates in the regulation
of phospholipid homeostasis necessary for maintaining cellular
membrane integrity. In particular, it acts as a phospholipase B pro-
moting phospatidylcholine conversion to glycerophosphocholine.
Knockout experiments show that it is indispensable for survival of
the embryo and maintenance of axons in adults; acetylation of gan-
gliosides and glycoproteins may also play a signiﬁcant role (Moser
et al., 2004).
Abnormal DNA repair
AP5Z1 is a putative helicasewith both nuclear and cytoplasmic local-
ization (Słabicki et al., 2010). It interacts with four proteins, probably
forming a complex required for an efﬁcient homologous recombination
DNA double-strand break repair. Two of the interaction partners,
spatacsin and spastizin, are proteins associatedwith spastic paraparesis.
Indeed, spatacsin is phosphorylated upon DNA damage by protein
kinases ATM (ataxia telangiectasia mutated) or ATR (ATM and Rad3-
related).
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MPLP is involved in myelin sheath stabilization and axon–myelin
interactions, whereas DM20, its splicing variant, is involved in oligoden-
drocyte maturation (Inoue, 2005). The large part of misfolded MPLP/
DM20 is retained in the ER. The presence of misfolded proteins induces
a cascade of protein interactions and dissociations. The chaperone bind-
ing immunoglobulin protein (BiP) associates with three stress sensors
(PERK, IRE1, and ATF6), maintaining these proteins in an inactive
state. Upon stress induction, BiP dissociates, translocates to the ER
lumen to assist in protein folding, and the sensor proteins adopt an
active status. The activated proteins induce a series of interacting path-
ways constituting the UPR that leads to apoptosis of oligodendrocytes
(Swanton et al., 2003).
FA2H is an NADPH-dependent monooxygenase highly expressed
in oligodendrocytes and it is involved in the biosynthesis of mamma-
lian sphingolipids (Lamari et al., 2013). FA2H synthesizes 2-hydroxy
fatty acids: these are incorporated into ceramide, a precursor of
galactosylceramide and one of the major constituents of the myelin
sheath. 2-hydroxylation stabilizes lateral interactions between
sphingolipids and membrane–membrane interactions (Zöller et al.,
2008). An alteration of this mechanism suggests that transport
and/or degradation of myelin components might be affected.
GJC2 mutations disrupt junction channels between astrocytes and
oligodendrocytes causing cell–cell communication impairment in
maintenance of CNS myelin (Orthmann-Murphy et al., 2009).
Autophagy
It was hypothesized that the truncated KIAA0329 protein would
lead to dysregulation of the intracellular autophagy pathway, with
reduced delivery of two targeted autophagocytic proteins (SQSTM1
and MAP1LC3B) to lysosomes (Oz-Levi et al., 2012).
Spastizin has been suggested to be associated with the AP5 complex
in endolysosomal function (Khundadze et al., 2013). In lymphoblast and
ﬁbroblast cells derived from spastizin mutated patients, it has been
demonstrated an impairment of autophagosomematurationwith accu-
mulation of immature autophagosomes (Vantaggiato et al., 2013).
Axon development
Neural cell adhesion molecule (NCAM) plays an important role in
the development of the nervous system, promoting neuron–neuron ad-
hesion and axon outgrowth. These crucial cellular events are permitted
by NCAM interactions with other cell adhesion molecules (CAMs).
NCAM molecular partners determine its function; in fact, NCAM-
integrin binding modulates adhesion to extracellular matrix proteins,
whereas the interaction between NCAM and TAG1 (transient axonal
glycoprotein-1) is necessary for NCAM–NCAM mediated neurite out-
growth (Kenwrick et al., 2000).
MCT8 is expressed in neurons and cerebral microvessels in all
species; its role in the transport of T4 from the blood into the cerebro-
spinal ﬂuid and in efﬂux of thyroid hormones or their inactive metabo-
lites from the cerebrospinal ﬂuid to blood was also suggested as a cause
of axon impairment (Roberts et al., 2008).
Endosome membrane trafﬁcking and vesicle formation
Adaptor protein complexes (AP1–4) are ubiquitously expressed and
mediate different types of vesicle formation and their molecular cargo se-
lection from the trans-Golgi compartment to the endosomal–lysosomal
system. AP4-mediated trafﬁcking can be involved in brain development
and functioning (Abou Jamra et al., 2011). It is also involved in the trans-
port of amyloid precursor protein (APP) from the trans-Golgi network to
early endosomes (Burgos et al., 2010).VPS37A is a component and an upstream regulator of the ESCRT-I;
its depletion delays EGF receptor degradation (Bache et al., 2004).
Strumpellin is a component of the Wiskott–Aldrich syndrome pro-
tein and scar homolog (WASH) complex, an actin-regulating complex
present at the surface of endosomes,which regulates the correct subcel-
lular distribution of the β-2-adrenergic receptor; corticospinal neurons
are especially vulnerable to reductions in functional WASH (Freeman
et al., 2013).
Abnormal cellular signaling in protein morphogenesis
Atlastin-1, NIPA1, spastin, and spartin have been shown to inhibit
bone morphogenetic protein (BMP) signaling (Tsang et al., 2009). This
suggests that the up-regulation of BMP pathway by loss-of-function
mutation in these genes could be a common pathogenic mechanism in
the disease.
Atlastin-1 regulates the axons architecture by down-regulating BMP
signaling during zebraﬁsh development (Fassier et al., 2010). As a mat-
ter of fact, the early depletion of this protein leads to severe defects in
axons, with consequent marked decrease of larval mobility. Functional
studies have demonstrated that atlastin-1 partially co-localizes with
BMP receptor type I in late endosomes, probably regulating the receptor
trafﬁcking.
NIPA1 protein is mainly expressed in early endosomes and cell sur-
face. It contains nine transmembrane domains and it is suggested to
partake in cellular magnesium metabolism. Recent evidences show
that NIPA1 and atlastin-1 are direct binding partners, since cellular dis-
tribution of atlastin-1/NIPA1 complexes is dramatically altered by
HSP-causing mutations (Botzolakis et al., 2011). In addition, NIPA1
inhibits BMP signaling by promoting endocytosis and lysosomal degra-
dation of the type II BMP receptor (BMPRII).Mutant NIPA1 is retained in
the ER and alters BMPRII trafﬁcking (Tsang et al., 2009).
Spartin is involved in epidermal growth factor receptor (EGFR)
intracellular trafﬁcking and an impaired endocytosis of EGFR bymutant
spartin would cause the onset of Troyer syndrome. Low levels of EGF
cause the internalization of EGFR via clathrin-mediated endocytosis.
Spartin knockdown decreases the rate of EGFR degradation and
affects EGFR internalization, recycling, or both. Conversely, spartin
over-expression results in a prominent decrease in EGFR degradation.
The molecular mechanisms leading to the redistribution of spartin are
unknown. It is believed that EGFR activation might induce the phos-
phorylation of spartin, leading to its translocation to the plasma mem-
brane (Bakowska et al., 2007).
SPFH2 is a proteinwith the ability to assemble into oligomeric struc-
tures and localize in cholesterol-rich membranes (Pearce et al., 2009).
As previously mentioned, it is involved in the ER degradation pathway
that target both aberrant and normal proteins to maintain homeostasis.
SPFH2 depletion causes impaireddegradation of inositol-1,4,5-trisphos-
phate (IP3); it leads to a persistent activation of IP3 signaling and chan-
nel opening, determining neuronal hyperactivity (Alazami et al., 2011).
Abnormal membrane trafﬁc and organelle shaping
Spastin, atlastin, REEP1, and reticulon 2 take part in ER membrane
modeling and shaping. These proteins share similar hairpin loops that
control ER membrane shaping.
Reticulon 2 overexpression determines the formation of tubular ER
membrane structures. It acts together with DP1/Yop1 proteins in stabiliz-
ing the ERmembrane curvature at the sheets edges. Moreover, the differ-
ent quantitative expression of these proteins is responsible for ER
morphology (Shibata et al., 2010). Atlastin controls ER tubules fusion in
order to create the ER network; it is noteworthy that morphology of the
tubular ER depends on microtubules dynamics that, in turn, depend
on spastin function. Mutual interactions between spastin, REEP1, and
atlastin-1 make these peptides responsible for the ER network formation
andmembrane bending. A truncated REEP1 protein causes the disruption
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hypothesis expects that these three proteins cooperate in protein trafﬁck-
ing alongmicrotubules and the loss of functionof thesepeptides leads to a
damage of the long axons of the corticospinal tract (Park et al., 2010).
Diagnosis
HSP can be suspected when the following differential diagnoses have
been excluded: leukodystrophies, subacute combined degeneration of
spinal cord (vitamin B12 deﬁciency), multiple sclerosis (absence of
oligoclonal bands in CSF in HSP), acyl-CoA dehydrogenase deﬁciency
(VLCAD), copper deﬁciency, Segawa disease (DYT5), HTLV-1-associated
myelopathy, amyotrophic lateral sclerosis, primary lateral sclerosis,
arginase deﬁciency, Friedreich's ataxia, mitochondrial disorders, early
onset Alzheimer disease with spastic paraparesis caused by presenilin 1
mutations, structural abnormalities of brain and spinal cord, and lumbar
vertebral stenosis. Also, spinocerebellar ataxias (SCA) can mimic HSP:
SCA3 (ATXN3) and autosomal recessive SCA (APTX, SETX, POLG, TDP1,
SACS, SYNE1, C10orf2, SCAR3, and SCAR7) should be excluded in selected
patients.
Diagnostic steps include individual and family history to detect the
type of transmission. A careful neurological examination, neurophysio-
logical testing, and instrumental investigations (MEPs, SEPs, VEPs, AEPs,
electroneurography/EMG, MRI, EEG, and cystometry) are needed in
diagnosis; pure and complex forms shall be identiﬁed before starting
genetic testing. Prolonged central conduction time in MEPs and SEPs
indicates the central long tract impairment. Neuroimaging analyses
would provide early clues to the diagnosis of HSP. Thinning or atrophy
of corpus callosum as well as cervical and thoracic spinal cord has been
observed on conventional MRI studies (Lan et al., 2014; Orlacchio
et al., 2011). Diffusion tensor imaging (DTI) successfully showed HSP-
related microstructural alterations in white matter. DTI could reveal
abnormality of white matter integrity, especially at the corticospinal
tract, in the early stage of SPG4 (Duning et al., 2010). Speciﬁc statistical
analyses clearly showed alterations in multiple DTI indices, such as de-
creased fractional anisotropy and increased radial diffusivity, indicating
loss of myelin integrity in HSP patients, including SPG3, SPG4, SPG5,
SPG7, and SPG10. Intriguingly, a decreased fractional anisotropy was
observed in the frontal circuitry, suggesting subtle disruption of the
frontal connections (Aghakhanyan et al., 2014). Neuropathological
investigations may detect axonal degeneration of the corticospinal
tract, loss of anterior horn cells, or demyelination consistentwith axonal
degeneration (Deluca et al., 2004).
Screening for SPG mutations is usually carried out by direct Sanger
sequencing coupled with multiplex ligation-dependent probe ampliﬁ-
cation (Battini et al., 2011). The improvement of nucleotide sequencing
has recently demonstrated the possibility of accelerating and improving
cost-effectiveness of genetic diagnosis using an array-based ampliﬁca-
tion strategy after generation of amplicon libraries of all currently
known HSP genes followed by a pooled next-generation sequencing
(NGS) (Chase, 2014; Novarino et al., 2014; Schlipf et al., 2011). Besides,
modern methodologies of re-sequencing have been reported (Kumar
et al., 2013) as well as a gene chip screening (Luo et al., 2013).
Beingmolecular genetic testing available on a routine basis only for a
few HSP forms (SPG3A, SPG4, SPG6, SPG7, SPG10, SPG11, SPG17, and
SPG31) we propose two algorithms (Fig. 3) for genetic testing.
Treatment
Treatment is exclusively symptomatic. Spasticity beneﬁts from daily
physical therapy (swimming, in particular), baclofen or tizanidine. If
ineffective, intramuscular injections of botulinum toxins A or B can be
considered, especially in cases associated with dystonia (Geva-Dayan
et al., 2010). Long-term intrathecal baclofen therapy can be adminis-
tered via a surgically implanted programmable pump (Motta and
Antonello, 2014). A recent study focused on gait and hydrotherapytreatment in patients with late onset HSP demonstrating increased
walking speed mediated by compensatory strategies (Zhang et al.,
2014). Deep brain stimulation has also been used in dystonia (Gilbert
et al., 2009). Hypertonic bladder beneﬁts from anticholinergic drugs
and neuropathic pain from gabapentin or pregabalin. Parkinsonism,
dementia, and epilepsy are treated according to the respective guide-
lines. Hearing devices in SPG29 and shunt implantations in SPG1 devel-
oping hydrocephalus are often used. Regular clinical revaluations of
patients once or twice yearly are recommended to assess progression
and complications.
Potential therapies
The availability of HSP animal models, including mouse, rat,
zebraﬁsh, cattle, Drosophila, and C. elegans (reviewed in Fink, 2013),
not only allows the exploration of disease mechanisms, but also of
potential treatments. Future prospects will allow a rational approach
to intracellular transport defects (Soderblom and Blackstone, 2006), in
particular microtubules dysfunction in SPG4 Drosophila models in
which mutated spastin leads to an excessive stabilization of microtu-
bules in the neuromuscular junction synapse: agents destabilizing
microtubules, like nocodazole (Trotta et al., 2004) and vinblastine
(Orlacchio et al., 2004b; Orso et al., 2005), seem to attenuate HSP-like
phenotypes in vivo.
If 27-hydroxycholesterol was a major factor in the degeneration of
corticospinal tracts in SPG5-patients, an effective therapeutic approach
should aim at reducing its levels. A possible therapeutic strategy
might be a statin treatment. It has been observed that the levels of 27-
hydroxycholesterol and cholesterol decrease in parallel during statin
therapy, limiting the synthesis (CYP27A1 activity) by a substrate avail-
ability (Schüle et al., 2010). Recent ﬁndings of moderate reductions of
serum 27-hydroxycholesterol upon simvastatin administration in
a SPG5-patient led to interesting possibilities on SPG5 treatment
(Mignarri et al., 2014).
A gene transfer study showed that adenoassociated virus-mediated
(AAV-mediated) intramuscular delivery of paraplegin halts the progres-
sion of neuropathological changes and rescues mitochondrial morphol-
ogy in the peripheral nerves of paraplegin-deﬁcient mice, suggesting
that viral vectors can be the key to treat genetic diseases (Pirozzi et al.,
2006).
Food for thought
Pure and late onset HSP forms are generally inherited following an
AD pattern, whereas ARHSPs often associate with early, more severe
onset, and complex phenotypes.
The evidence that degeneration may also regard shorter axons, for
example in the cerebellum, neocortex, corpus callosum, and optic nerve,
suggests that length-dependent distal axon degeneration is not the
only pathogenetic mechanism involved (White et al., 2000).
Different clinical features reﬂect genetic heterogeneity in HSP.
Many genes are implicated in selective clinical manifestations,
while the same gene is mutated in various diseases (see among
others, the ample allelisms of BSCL2 and FA2H). It is well known
that mutated genes alter speciﬁc intracellular (or cell-to-cell)
mechanisms bringing different clinical features. The identiﬁcation
of causative genes in HSP revealed that the common axonal degen-
eration has different pathogenetic mechanisms. This overlaps with
other neurodegenerative diseases, in particular distal spinal
muscolar atrophy (SMA), juvenile amyotrophic lateral sclerosis
(JALS), and CMT. Indeed, BICD2 mutations, encoding a key adaptor
protein involved in trafﬁcking of cellular cargos, are reported in patients
showing both HSP and autosomal dominant congenital SMA (DCSMA)
(Oates et al., 2013). Lower motor neuron degeneration in HSP overlaps
with JALS, as evidenced by the identiﬁcation of KIAA1840mutations in
40% of JALS-patients (Orlacchio et al., 2010) and by the dysfunction of
Fig. 3. Algorithms for genetic testing in pure (A) and complicated (B) HSP. SPG forms in ovals are reported following their relative frequencies from top to bottom. AD= autosomal dom-
inant; AR = autosomal recessive; CI = cognitive impairment; CS = cerebellar signs; OA= optic atrophy; PNP = polyneuropathy; TCC = thin corpus callosum; XL = X-linked.
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2007). This concept also concerns CMT neuropathies (primarily CMT2),
which show many similarities with HSP (reviewed in Timmerman et al.,
2013) in terms of clinical presentation, molecular genetics, and cellular
pathology. In particular, a KIF5Amutation, p.G235E, has been found in a
patient affected by axonal CMT and member of an HSP family; this sug-
gests that SPG10 and CMT may be the extreme phenotypes resulting
from mutations in the same gene (Crimella et al., 2012). Finally, by
using the random walk distance algorithm in HSP genes network,
Novarino et al. (2014) linked HSP to amyotrophic lateral sclerosis,
Alzheimer's disease, and Parkinson's disease.
Therefore, the recognition of common molecular themes in motor
neuron diseases could clarify the bases of neurodegeneration and justify
therapeutic strategies, which are not limited to individual subtypes, but
rather based on pathway/module impairment.
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